title: Exploiting Defective DNA Repair inIDH-Mutant Cancers.
abstract: Data from a preclinical study suggest rethinking the "oncometabolite hypothesis," which calls for blocking the product of neomorphicIDH1/2mutations to halt tumor progression. Instead, exploiting the vulnerability ofIDH1/2-mutant tumor cells to PARP inhibition, as a result of defective DNA repair, appears to be a more effective strategy that will soon be tested in the clinic.